PT-141 occupies a unique position in women’s sexual health: it is one of the very few compounds in the entire peptide conversation that was studied in women, approved for women, and works through a mechanism that has nothing to do with hormones or blood flow. It is also widely misunderstood — oversold by some vendors, dismissed by people who confuse it with male ED drugs. Here is the complete picture.
What PT-141 Is
PT-141 is the research name for bremelanotide, a synthetic cyclic peptide derived from Melanotan II. In 2019 the FDA approved it under the brand name Vyleesi for a specific condition: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — low sexual desire that causes real distress and isn’t explained by another medical condition, a relationship problem, or a medication. That made it only the second drug ever approved for HSDD, after Addyi in 2015, and the first that works on demand rather than daily.
How It Works: Desire, Not Plumbing
Male sexual medications like sildenafil work on blood flow. PT-141 works upstream, in the brain. It activates melanocortin receptors — MC4R and MC1R most relevantly — found in central nervous system regions involved in sexual desire pathways. The label itself is honest that the precise mechanism by which this improves HSDD is not fully understood, but the practical distinction matters enormously: this is a desire compound, not an arousal-mechanics compound. It is also why the same molecule has been researched in both women and men — desire circuitry is not gender-exclusive, though the FDA approval covers premenopausal women only.
How It's Used
As Vyleesi, the regimen is refreshingly simple: a 1.75 mg subcutaneous injection via prefilled autoinjector into the abdomen or thigh, at least 45 minutes before anticipated sexual activity. No more than one dose in 24 hours, no more than eight doses per month — and in the trials, most women used it just two or three times per month. The label also builds in an honesty checkpoint: if there is no improvement after eight weeks, discontinue. This is an as-needed tool, not a daily medication.
What the Trials Actually Showed
Approval rested on the RECONNECT trials — two placebo-controlled studies enrolling over 1,200 premenopausal women with HSDD. The results were statistically real and clinically modest: roughly a quarter of women on bremelanotide had a meaningful increase in their sexual desire score, versus about 17% on placebo. Read that honestly. PT-141 helps a meaningful subset of women noticeably; it is not a switch that transforms desire for everyone. Anyone selling it as guaranteed is selling.
Side Effects Women Should Actually Know About
- Nausea is the headline side effect — the most common reaction in trials, sometimes strong enough that women discontinued. It tends to be worst with the first doses.
- A temporary blood pressure rise follows each dose (a few points systolic, resolving within about 12 hours). This is why Vyleesi is not recommended for women with uncontrolled hypertension or high cardiovascular risk — and why the once-per-24-hours rule exists.
- Focal hyperpigmentation — darkening of skin on the face, gums, or breasts — occurred in about 1% of women at labeled doses, with higher risk in darker skin tones and with more frequent dosing. Critically, it did not always resolve after stopping. The melanocortin system PT-141 activates includes the receptor that drives melanin production; this is the same biology that made its parent compound a tanning agent.
- Flushing, headache, and injection-site reactions round out the common list.
- Naltrexone users take note: bremelanotide can reduce the effectiveness of oral naltrexone — a serious problem if it is treating alcohol or opioid use disorder. It can also slow absorption of other oral medications.
- Pregnancy is a stop sign: the label advises effective contraception and discontinuing if pregnancy is suspected.
One Genuinely Nice Detail: Alcohol
Unlike Addyi — whose history is defined by its alcohol interaction — bremelanotide’s studies found no problematic interaction with moderate alcohol consumption. For a medication used before intimate evenings, that is not a small practical difference. We compare the two head-to-head in PT-141 vs Addyi.
What If You're Postmenopausal?
The approval covers premenopausal women only — not because it was shown to fail after menopause, but because that is who the trials enrolled. Postmenopausal use is therefore an off-label conversation with a provider, weighing the cardiovascular considerations that become more relevant with age. Desire changes after menopause deserve a full workup (hormonal, relational, medication review) before any compound; our menopause guide and the sexual wellness hub map the territory.
How Women Actually Access PT-141
- Vyleesi (the approved product): still actively marketed in 2026, with telehealth prescribing and pharmacy home delivery. Typical 2026 pricing through the manufacturer’s channel: as little as $0 per four-dose box with commercial insurance, or around $99 cash — dramatically cheaper than the list prices quoted at retail pharmacies.
- Compounded bremelanotide: some compounding pharmacies dispense it with a prescription, typically as vials rather than autoinjectors. Compounded versions are not FDA-approved products and quality varies by pharmacy.
- Research vendors: PT-141 is widely sold for research purposes. The considerations we lay out in our compounded vs research vs prescribed guide apply in full — with the added note that this particular compound’s blood-pressure effect and hyperpigmentation risk are exactly the kind of thing a prescriber screens for.
Full details on approval status and legality: Is PT-141 FDA approved?